What is BioMarin Pharmaceuticals's VOXZOGO — revenue?

BioMarin Pharmaceuticals (BMRN) reported VOXZOGO — revenue of $57.44M in Q4 2022.

What does VOXZOGO — revenue mean?

The net revenue generated from the sales of a specific pharmaceutical product.

How do you interpret VOXZOGO — revenue?

Rising revenue suggests strong clinical demand and effective commercial execution, whereas declining revenue may reflect pricing pressure or shifts in the competitive landscape for that specific therapy.

How does VOXZOGO — revenue compare across companies?

Similar to individual product revenue line items disclosed by peer biotech firms to demonstrate the performance of key commercialized therapies.

BioMarin Pharmaceuticals BMRN VOXZOGO — Revenue

Discontinued — last reported Q4 '22

Similar metrics at other companies

INCYOPZELURA — Total revenues

$143.02M+20.5%

ROIVProduct revenue, net — Revenue, net

$0-100%

BIIBBYOOVIZ — Total Revenue

$0-100%

BBIONet product revenue — Revenue

$180.6M+392%

JAZZVyxeos — Revenue from Contract with Customer, Excluding Assessed Tax

$26.6M-9.8%

BBIOCommercial Product Supply — Revenue

$600K—

Other financials

Income statement

See full

Revenue$766.2M+2.8%

Gross profit$571.2M-3.8%

Operating income$129.6M-42.1%

Net income$105.5M-43.2%

EPS (diluted)$0.54-43.2%

Balance sheet

See full

Cash & equivalents$3.1B+193%

Total debt$1.4B+138%

Total equity$6.2B+7.2%

Total assets$8.6B+20.2%

Cash flow

See full

Operating cash flow$220.7M+26.5%

CapEx$20.9M+24.8%

Free cash flow$199.7M+26.7%

Valuation

See full

Market cap$10.57B-19.4%

Enterprise value$8.93B-29.3%

P/E21.1×-22.7×

P/S3.3×-1.2×

Profitability

See full

Gross margin76.5%-2.9pp

Operating margin19.9%+7.2pp

Net margin16.8%+5.1pp

FCF margin23.7%+2.5pp

Returns & leverage

See full

Return on equity9.1%+2.8pp

Debt / equity0.2×+0.1×

Current ratio5.8×+0.3×

Where this comes from

Reported directly by BioMarin Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: BioMarin Pharmaceuticals’s 10-K, filed February 27, 2023, on SEC EDGAR. View the filing →

Ask your AI about BioMarin Pharmaceuticals's voxzogo — revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is BioMarin Pharmaceuticals's VOXZOGO — revenue?: BioMarin Pharmaceuticals (BMRN) reported VOXZOGO — revenue of $57.44M in Q4 2022.
What does VOXZOGO — revenue mean?: The net revenue generated from the sales of a specific pharmaceutical product.
How do you interpret VOXZOGO — revenue?: Rising revenue suggests strong clinical demand and effective commercial execution, whereas declining revenue may reflect pricing pressure or shifts in the competitive landscape for that specific therapy.
How does VOXZOGO — revenue compare across companies?: Similar to individual product revenue line items disclosed by peer biotech firms to demonstrate the performance of key commercialized therapies.